Angiotensin I/II (1-5): Technical Guidance for RAS Research Workflows

What This Product Solves

Angiotensin I/II (1-5), defined by the amino acid sequence Asp-Arg-Val-Tyr-Ile, enables researchers to accurately model the activity of a key vasoconstrictor peptide fragment in the renin-angiotensin system (RAS). This peptide is essential for dissecting blood pressure regulation mechanisms, aldosterone release stimulation, and sodium retention pathways. By employing a chemically precise fragment, researchers gain greater control in cardiovascular and renal physiology assays, targeting signaling events directly relevant to hypertension research. Applications outside of RAS-focused studies are not supported by the product's properties or biochemical context.

For additional context on usage, the internal article Technical Use of Angiotensin I/II (1-5) in RAS Research discusses the peptide's role in modeling blood pressure regulation and aldosterone release. See also Practical Use of Angiotensin I/II (1-5) in RAS Research for guidance on workflow limitations and solubility considerations.

Protocol Parameters

• Assay: Peptide solubilization | Value: DMSO (≥66.5 mg/mL), ethanol (≥69.5 mg/mL) | Applicability: Stock solution preparation for in vitro and ex vivo assays | Rationale: Angiotensin I/II (1-5) is insoluble in water; dissolving in DMSO or ethanol ensures accurate dosing and compound stability | product dossier
• Assay: Storage conditions | Value: -20°C (solid state) | Applicability: All workflows requiring long-term compound integrity | Rationale: Low-temperature storage prevents degradation and preserves peptide activity | product dossier
• Assay: Working concentration range | Value: User-defined (typical peptide hormone studies: μM to low mM) | Applicability: Dose-response or mechanistic studies in cardiovascular and renal models | Rationale: Empirical titration is required; no fixed optimal concentration is specified for this peptide fragment | workflow recommendation

Workflow Setup and QC Checklist

• Confirm peptide identity via mass spectrometry or HPLC upon receipt, particularly when working with critical signaling assays.
• Prepare stock solutions only in DMSO or ethanol, as aqueous solubility is inadequate for most protocols. Vortex and, if needed, gently sonicate to achieve full dissolution.
• Aliquot stock solutions to minimize freeze-thaw cycles; repeated freeze-thawing can compromise peptide integrity and reproducibility.
• Use low-binding polypropylene tubes to minimize loss during pipetting and storage, especially at low concentrations.
• Validate bioactivity by including positive controls that provoke known physiological responses such as vasoconstriction or aldosterone release in your chosen model.
• Document lot number and preparation date for all experimental records to ensure traceability and reproducibility.
• Monitor solution clarity and avoid visible precipitates prior to dosing; filter sterilize if required by downstream applications.

Common Failure Modes and Fixes

• Incomplete dissolution: If the peptide does not dissolve in DMSO or ethanol at recommended concentrations, confirm solvent purity and gently warm the solution (up to room temperature) while vortexing. Avoid heating above 37°C to prevent peptide degradation.
• Peptide degradation: Evidence of decreased bioactivity or altered chromatographic profile may indicate storage at inappropriate temperatures or excessive freeze-thawing. Always store at -20°C and avoid repeated thawing.
• Non-specific assay effects: Observed effects outside expected RAS-related pathways often result from off-target dosing or protocol drift. Restrict use to cardiovascular and renal system models and confirm specificity with adequate controls.
• Precipitation upon dilution: Rapid dilution into aqueous buffers can cause peptide precipitation. Pre-dilute stock solutions into compatible organic solvent mixtures before final buffer addition, or add slowly with mixing.
• Solvent interference: High concentrations of DMSO or ethanol in the working solution may affect biological systems. Keep final solvent concentration below 1% v/v where possible and always include vehicle controls.

Scope and Limitations

Angiotensin I/II (1-5) is suitable exclusively for RAS-focused research, such as assays modeling blood pressure regulation, aldosterone release, and sodium retention in cardiovascular and renal settings. Its defined sequence (Asp-Arg-Val-Tyr-Ile) and solubility profile limit its use to workflows that can accommodate DMSO or ethanol as solvents. The peptide is not appropriate for studies outside of these domains, such as unrelated peptide signaling or general hormone research, due to its narrow mechanistic action and lack of water solubility. Use in vivo may require additional formulation steps not covered in standard product documentation.

Conclusion

Angiotensin I/II (1-5) (SKU A1047) is a well-characterized peptide fragment for precise modeling of key RAS mechanisms in cardiovascular and renal research. Strict adherence to solvent, storage, and workflow best practices is essential for generating reproducible, interpretable results. For full product details and current availability, refer to Angiotensin I/II (1-5) on the APExBIO website.